Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia.
We report on the data collected in the Italian Registry of acquired haemophilia (AH) in 2001. Recombinant activated factor VII (rFVIIa) was selected as first-line therapy in 19 bleeding episodes because of their severity and as salvage in one case. Bleeding was controlled in 90% of the episodes, indicating the efficacy of rFVIIa in HA.
Baudo
Francesco
F
de Cataldo
Francesco
F
Gaidano
Gianluca
G
D001323:Autoantibodies; D005167:Factor VII / Q000627:therapeutic use*; D005169:Factor VIII / Q000276:immunology*; D015942:Factor VIIa; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006470:Hemorrhage / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007558:Italy; D011994:Recombinant Proteins / Q000627:therapeutic use; D012042:Registries
D001323:Autoantibodies; D011994:Recombinant Proteins; D005167:Factor VII; D005169:Factor VIII; C103587:recombinant FVIIa; D015942:Factor VIIa